

# PLACE

PLATFORM OF LABORATORIES FOR ADVANCES IN CARDIAC EXPERIENCE



## ROMA 2024

- 12 Giugno MINICORSI Precongressuali
- 13-15 Giugno CONGRESSO

**CARDIOMIOPATIA DILATATIVA NON ISCHEMICA E PROLASSO VALVOLARE ARITMICO**


# Prolasso mitralico aritmico: un approccio imaging guidato nel paziente asintomatico

Pellegrino Ciampi, MD  
Policlinico Casilino  
Roma




# Mitral valve prolapse: anatomopathological definition

Degenerative mitral valve disease characterized by pathological remodeling of the leaflets with two distinct phenotypes, fibroelastic deficiency (FED) and Barlow's disease



FED



Barlow's disease

# Clinical implications



Leading cause of **degenerative mitral regurgitation (DMR)** in the Western world

**Congestive heart failure** (volume overload)

**Endocarditis** (arterial embolism)

**Rhythm disorder** (from premature ventricular contractions through arrhythmic sudden death) – “**arrhythmic and malignant MVP**”

- AMVP due to severe DMR
- AMVP with severe myxomatous disease irrespective of DMR




# Epidemiology

Estimated prevalence in the general population **2-3%**


## MVP-Related SCD:

- **3x** risk of general population
- Estimated risk is **0.2% to 1.8%**
- Implicated in **1.9%** of SCD in a recent meta-analysis (*Nalliah CJ et al. Heart 2019*)

**A** Annual incidence of sudden cardiac death



Muthukumar et al. JAMA Cardiology 2020







# aMVP: Can we draw a patient identikit?

## Demographic, clinical and electrocardiographic risk factors

- Female prevalence (young age – 30 years)
- Chest pain, palpitations, dyspnoea on exercise comparable incidence in pts with and without MVP (Framingham study) – unexplained syncope may have high discriminative value
- T wave inversion or biphasic T wave in inferior and lateral leads
- QT prolongation
- Fragmented QRS




## Premature ventricular contractions and Holter monitoring

**Table 3** Arrhythmia severity classification

| Severity                                     | Arrhythmia burden/rate                                   | Risk of mortality<br>HR [95% CI] | References |
|--|--|----------------------------------|------------|
| <b>Mild</b><br>ventricular<br>arrhythmia     | PVC≥5% and/or<br>VT runs<br><120 bpm                     | 1.20 [0.68–2.14],<br>P = 0.5     | 14         |
| <b>Moderate</b><br>ventricular<br>arrhythmia | VT runs<br>120–179 bpm                                   |                                  |            |
| <b>Severe</b><br>ventricular<br>arrhythmia   | VT runs ≥180 bpm<br>and/or history of<br>sustained VT/VF | 2.94 [1.36–6.36]<br>P = 0.006    |            |



HR, hazard ratio; PVC, premature ventricular contractions; VT, ventricular tachycardia.



Essayagh B et al, JACC 2020



# Identifying MVP at risk for ventricular arrhythmia and SCD: do imaging tools help?

- superior systolic **displacement** of the mitral valve leaflet of **> 2mm**
- Quantification of **MR severity** (integration of qualitative, semi-quantitative and quantitative parameters)
- Assessment of **LV remodelling** and both **regional** and **global LV function**
- High prevalence of LGE, abnormal LV dilatation, > 1% PVC, %NSVT/VT/VF in patients with trace-mild MR! **MVP-associated cardiomyopathy?**



## Echocardiographic predictors of arrhythmias


- severe myxomatous degeneration (thick and redundant leaflets with multi-segment bileaflet MVP)
- Systolic Curling (ballerina foot deformity)
- Mitral annulus disjunction (MAD)





## MAD or MADNESS

- Systolic separation between the ventricular myocardium and the mitral annulus supporting the PML (> 8.5 mm strong predictor for NSVT)
- Variable prevalence in different MVP cohort studies**
- A significant prevalence in structurally normal hearts**
- Association with a higher risk of arrhythmic events but not with a higher mortality**
- Association of MAD with VT/aborted cardiac arrest in patients without MVP: a **MAD arrhythmic syndrome?**



European Heart Journal - Cardiovascular Imaging (2021) 22, 614–622  
European Society of Cardiology doi:10.1093/ehjci/ebab022


## Prevalence and extent of mitral annular disjunction in structurally normal hearts: comprehensive 3D analysis using cardiac computed tomography

Hiroyuki Toh<sup>1</sup>, Shumpei Mori<sup>2\*</sup>, Yu Izawa<sup>1</sup>, Hiroshi Fujita<sup>1</sup>, Keisuke Miwa<sup>1</sup>, Masataka Suzuki<sup>1</sup>, Yu Takahashi<sup>1</sup>, Takayoshi Toba<sup>1</sup>, Yoshiaki Watanabe<sup>3</sup>, Atsushi K. Kono<sup>3</sup>, Justin T. Tretter<sup>4</sup>, and Ken-ichi Hirata<sup>1</sup>

**Table 1** Prevalence of mitral annular disjunction

| Study                                | Year | Population  | Prevalence of MAD, n/N (%) |
|--------------------------------------|------|---|----------------------------|
| <b>TTE</b>                           |      |   |                            |
| Carmo et al. <sup>22</sup>           | 2010 | Myxomatous mitral valve prolapse                      | 21/38 (55)                 |
| Lee et al. <sup>27</sup>             | 2017 | Mitral valve prolapse                                 | 42/156 (27)                |
| Konda et al. <sup>20</sup>           | 2017 | Patients referred for TTE                             | 125/1439 (9)               |
| Mantegazza et al. <sup>28</sup>      | 2019 | Mitral valve prolapse, severe MR                      | 103/979 (16)               |
| Torras et al. <sup>29</sup>          | 2019 | Mitral valve prolapse                                 | 22/101 (22)                |
| Essayagh et al. <sup>19</sup>        | 2021 | Mitral valve prolapse                                 | 186/596 (31)               |
| Essayagh et al. <sup>30</sup>        | 2021 | Mitral valve prolapse and severe MR undergoing repair | 27/61 (44)                 |
| <b>CMR</b>                           |      |   |                            |
| Christiansen et al. <sup>21</sup>    | 2010 | Mitral valve prolapse undergoing CMR                  | 18/31 (58)                 |
| Perazzolo Marra et al. <sup>16</sup> | 2016 | Arrhythmic myxomatous mitral valve prolapse           | 37/52 (71)                 |
| Essayagh et al. <sup>32</sup>        | 2019 | Mitral valve prolapse                                 | 31/89 (35)                 |
| Zugwilt et al. <sup>33</sup>         | 2022 | UK Biobank imaging study participants                 | 1990/2607 (76)             |
| Figliozzi et al. <sup>26</sup>       | 2023 | Mitral valve prolapse                                 | 321/474 (68)               |



## CENTRAL ILLUSTRATION Mitral Annulus Disjunction (MAD) Arrhythmic Syndrome



Dejaard, L.A. et al. J Am Coll Cardiol. 2018;72(14):1600-9.



# True MAD vs the «new» concept of pseudo-MAD

- The «**systolic MAD**» or **pseudo-MAD**, most common, result of a juxtaposition of the belly of the billowing PL on the adjacent LA wall
- The «**true MAD**», more rare, when the insertion of PL at hinge line is clearly displaced on the atrial wall either in **diastole** or in **systole**



# Echocardiographic predictors of arrhythmias: novel echo findings


- **Pickelhaube sign**: marker of abrupt forceful myocardial stretch ( $>16\text{ cm/s}$  associated with VA, highest signal velocity in the **posterolateral annulus**)
- **Speckle tracking echocardiography**: ventricular repolarization heterogeneity – electromechanical dissynchrony, ventricular hyperexcitability
  - Supranormal peak longitudinal strain in infero-lateral mid-basal ventricular segments
  - Mechanical dispersion
  - Postsystolic strain index (PSI)
  - Double peak strain pattern





## CMR predictors of arrhythmias



- **variable prevalence** rates of different pattern of **replacement fibrosis** (mid wall, patchy, or subendocardial) of the **PPM** and **infero basal LV wall** by LGE in patients with arrhythmic MVP (**28-37%**)
- strong correlation of LGE and arrhythmic events/SCD despite MR severity (**25%** of LGE in pts with **mild MR**)
- Future studies will determine whether burden/patterns of LGE enhance arrhythmic risk stratification in pts with MVP
- Most patients with MVP and VA have scar, but not all!
- In a retrospective analysis by Garbi et al of SCD cases with MVP, **81%** had either **diffuse interstitial fibrosis** or **none** (role of **T1 mapping** to detect arrhythmic risk in MVP pts)





# Clinical Case

- Female, 37 y/o
- neither CV risk factors nor family history of CM and SCD
- Episodic palpitations, nor syncope or presyncope
- EKG: SR, inverted T waves in DIII, flattened T waves in lateral leads, PVCs RBBB superior axis morphology
- Holter EKG: 2884 PVC (2.9%), 2 NSVT




# Echocardiographic findings

- severe myxomatous degeneration (thick and redundant leaflets with multi-segment bileaflet MVP)
- Mild to moderate MR
- Severe LA dilatation, mild LV dilatation with normal LVEF
- Curling, Pickelhaube sign (TDI S' 23 cm/s), systolic MAD 6 mm
- Excessively increased (more negative) segmental LS in basal and mid lateral segments with increased electro-mechanical dyssynchrony (MD and PSI ↑↑ )



## CMR findings


- LV and LA dilatation, preserved LV function;
- Mild MR;
- Basal curling;
- True MAD 5 mm;
- No LGE, normal native myocardial T1, ↑ ECV in basal infero-lateral segment





# Treatment and follow up

- ILR implantation
- Medical therapy with Nadolol and Flecainide
- No symptoms
- Reduction of arrhythmic burden without high risk VT at follow up





# Take Home Messages

- When diagnosing MVP, it is important to consider an aMVP phenotype, also irrespective of DMR severity
- MVP diagnosis requires a 24h Holter-ECG also in asymptomatic patients without severe VA at index monitoring because arrhythmic risk in MVP is progressive over time
- Multimodality imaging plays a pivotal role in aMVP phenotypic characterisation and should be advised as part of routine follow up
- Longitudinal studies and prospective outcome data are needed to determine the predictive value of all the currently available risk stratification imaging tools